A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 27 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 20 Nov 2017.
- 15 Sep 2017 New trial record